Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant anlotinib plus chemotherapy for esophageal malignant tumor
ChiCTR2100054374Phase 4Not yet recruiting
- Sponsor
- Henan Provincial Chest Hospital
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anlotinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Henan Provincial Chest Hospital. Primary endpoint: Pathologic complete response. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2100054374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054374.